display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR positive - L1 - PIK3CA mutant
AKT inhibitor
ipatasertib based treatment
ipatasertib plus paclitaxel IPATunity130

Study type: